Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn 15,447 adults from the NIH All of Us program, published in July in Alcohol, Clinical and Experimental Research, current GLP-1 users scored 5 to 11 percent lower on a standard alcohol screen than people about to start the drug. The whole effect came from drinking on fewer days. Drinks per occasion and binge drinking did not budge, a frequency-not-intensity split that reframes the hope that these drugs curb alcohol use disorder.
A real-world study of about 330,000 matched patients published July 8 in Digestive Diseases and Sciences puts hard numbers on the GLP-1 gut toll: 31.9 percent had a gastrointestinal adverse event within a year, gastroparesis was 57 percent more likely, and drug-induced pancreatitis nearly tripled. But the same data cut both ways, with fewer bowel obstructions, null gallbladder findings, and fewer emergency-room visits and hospital admissions overall.
The full phase 3 TRANSCEND data published July 9 in the New England Journal of Medicine: setmelanotide dropped body-mass index 16.5 percent over a year in acquired hypothalamic obesity while placebo gained 3.3 percent. Read against Rhythm's EMANATE failure in partial-loss obesity two months ago, it draws a clean line: the MC4R agonist works only where the melanocortin satiety circuit is fully broken, whether a mutation silenced it or a tumor destroyed the tissue around it.
ARCADIAMP, a generative AI that writes peptide sequences the way image models write pixels, produced ten antimicrobial candidates. Eight killed bacteria, and the lead one, Arcinin, cleared drug-resistant ESKAPE pathogens while sparing human cells and healing infected wounds in mice.
A single-center Japanese cohort of 34 adolescents aged 15 to 17 found CGRP monoclonal antibodies cut migraine impact by 9.4 HIT-6 points at 12 weeks, with about half of responders improving by weeks four to six and no serious side effects.
Tirzepatide activates the GIP receptor. MariTide blocks it. Both cause weight loss, and the field cannot say which is right. A new mouse study built a single peptide that does both in sequence, and the on-then-off design dropped body weight 21.6 percent, against 14.5 percent for a pure blocker.
Ecnoglutide, from Sciwind Biosciences, is the first GLP-1 drug built to drive one signaling arm and ease off another. China cleared it for diabetes and obesity six weeks apart, and Pfizer paid up to $495 million for the China rights. Its roughly 15 percent weight loss has not yet beaten the incumbents.
A meta-analysis of nine trials found the dual GLP-1 and glucagon agonist mazdutide cut weight by 6.6 to 11.1 percent across rising doses in obesity, and beat dulaglutide on weight and blood sugar in diabetes. The reviewers rated the obesity numbers very low certainty and the diabetes numbers moderate.
A study across 13 South Korean hospitals found adults who started semaglutide or liraglutide to lose weight were diagnosed with depression, anxiety, and other problems more often than matched non-users, with semaglutide carrying about 3.4 times the depression rate. The comparator was people not on the drug, so detection bias could be doing much of the work.
The FDA's complete response letter for gallium-68 edotreotide raised no issue with the clinical data, only with the contract facility that makes the dose.
A retrospective study of 21,250 US patients found adults with chronic pancreatitis on GLP-1 drugs were 41 percent less likely to start long-term opioids, and had fewer nerve blocks, endoscopic procedures, and pancreatic surgeries. It is an association from hospital records, not proof the drugs ease the disease.
A network meta-analysis of 17 trials and 1,230 adolescents ranked semaglutide best for weight, dulaglutide for blood sugar, and others for glucose and blood pressure. But most comparisons were indirect and single-trial, so the leaderboard is a hypothesis, not a head-to-head result.
In 371 adults, semaglutide cut blood eosinophils, a driver of asthma inflammation, by about a third. The drop was bigger in leaner patients and independent of weight lost, pointing at a direct effect on type 2 inflammation.
A protein called CAP builds up in the gut of children with Hirschsprung disease and stalls the nerve cells that should colonize the colon. A fragment of that same protein, PDCAP, competes it off, and in two mouse models it let the missing nerves form.
Six phase 1 studies mapped orforglipron's drug interactions. A CYP3A4-blocking antibiotic raised the oral GLP-1 drug's levels, an epilepsy drug lowered them, and orforglipron barely touched other drugs. The injectable peptides carry no such map.